GRK4 Polymorphisms Blood Pressure Response to Candesartan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT01629225

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01629225
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01629225. Allocation not applicable; single masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GRK4 Polymorphisms Blood Pressure Response to Candesartan
Condition
Essential Hypertension
Intervention (Drug)
Candesartan
Lead sponsor
Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct01629225
Content hash
2e6c4c8074675881ba65816f7801106c66de4360a303be78b6f7fd23737773fd